Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SWITCH-2 sequence trial of sorafenib and pazopanib in advanced renal cell carcinoma
NL-OMON43677Phase 3Active, not recruiting
- Sponsor
- Technical University of Munich Faculty of Medicine
- Start
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sorafenib and pazopanib in renal cell carcinoma (RCC) (2 arms), sponsored by Technical University of Munich Faculty of Medicine. Primary endpoint: Total progression-free survival. Started Jan 2013; status: active, not recruiting.
02
Drugs
sorafenibpazopanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON43677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43677.